Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.25
Bid: 14.00
Ask: 14.50
Change: 0.00 (0.00%)
Spread: 0.50 (3.571%)
Open: 14.25
High: 14.25
Low: 14.00
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

1 Aug 2005 07:01

Angle PLC01 August 2005 For Immediate Release 1 August 2005 ANGLE plc ("ANGLE" or the "Company") Formation of Executive Management Board and Board Change ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-based industryannounces the formation of an Executive Management Board which will reportdirectly to the ANGLE plc Board. In recognition of the Company's recent successes, rapid expansion and futureprospects across the United Kingdom, United States and the Middle East, ANGLEhas strengthened its management structure and promoted Stephen Bates, currentlyDirector of UK Ventures, to UK Chief Executive. Responsibility for HR,marketing, IT and operations will now be devolved from the Board to regionalchief executives ensuring full responsibility for all activities in theirrespective regions. With immediate effect, the Executive Management Board will consist of Group CEO,Andrew Newland and Finance Director, Ian Griffiths, together with: Stephen Bates, UK Chief Executive Stephen Bates has an MA in engineering, and an MBA. Following 10 years withinthe product development industry his career has taken him to ScientificGenerics, Arthur D. Little and Marks & Spencer prior to joining ANGLE in 2004.Dr Gary Evans, US Chief Executive Gary Evans has a BSc in Chemistry, a PhD in Physical Chemistry, and a Diploma inManagement Science and was Visiting Professor in Innovation Management at theRobert Gordon University, Aberdeen. Following a career with Cambridge LifeSciences and then Scottish Enterprise, Dr. Evans joined ANGLE in 1997. Dr Eulian Roberts, Middle East Chief Executive Eulian Roberts has a BSc in Microbiology, a PhD in Molecular Biology and an MBA.He gained three years' post-doctoral experience and then joined ScottishEnterprise. He then became chief executive of the Stirling University InnovationPark, managing director of Coventry University Enterprises Limited and adirector of the UK Science Park Association. Dr Roberts joined ANGLE in 1998. As a result of these changes, Dawson Buck will be stepping down from hisposition as Deputy Chief Executive, with immediate effect. He remains a directorof ANGLE's venture companies, Corpora plc and Provexis plc. Commenting on the new organisational structure, Group CEO, Andrew Newland, said: "The formation of an Executive Management Board establishes a clear managementstructure and accountability by region which will improve the efficiency andintegration of our Consulting & Management and Ventures operations, streamlineoverheads and facilitate our continuing rapid growth. The new management structure gives us the platform we need to grow the businesssubstantially. I am delighted to have such high calibre individuals within theExecutive Management Board. I would also like to put on record my thanks to Dawson Buck for all hiscontributions to the ANGLE Board over the last five years." For further information ANGLE plcAndrew Newland, Chief Executive Tel: +44 (0)1483 295830 Buchanan Communications Tel: +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L); further information can be found onwww.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
13th Sep 20175:36 pmRNSHolding(s) in Company
13th Sep 20177:00 amRNSExclusive worldwide option over megakaryocyte IP
11th Sep 20177:00 amRNSCo-Marketing Partnership with QIAGEN
5th Sep 20177:00 amRNSChange of Adviser
4th Sep 20177:00 amRNSNew Research with Parsortix
27th Jul 20177:00 amRNSPreliminary Results
20th Jul 20171:00 pmRNSPreclinical Study Presented At Tumor Boston Summit
6th Jul 201710:05 amRNSNotice of Results
4th Jul 20177:00 amRNSSuccessful Headline Data in Ovarian Cancer Studies
15th Jun 20177:00 amRNSParsortix breakthrough in prostate cancer
5th Jun 20177:00 amRNSSuccess with Parsortix in Colorectal Cancer
3rd May 20177:00 amRNSBusiness Update
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSParsortix enables analysis in head and neck cancer
30th Mar 20177:00 amRNSProstate Cancer Update
14th Feb 201711:39 amEQSEdison issues outlook on Angle
13th Feb 20177:00 amRNSSelected for European Cancer ID Programme
26th Jan 20177:01 amRNSInterim Evaluation of Ovarian Cancer Study
26th Jan 20177:00 amRNSInterim Results
4th Jan 20177:00 amRNSNotice of Results
28th Nov 20167:00 amRNSISSUE OF SHARE OPTIONS
24th Nov 20162:48 pmRNSResult of GM
4th Nov 20167:00 amRNSBarts Research Supports Potential Use of Parsortix
1st Nov 20167:00 amRNSNotice of GM
27th Oct 20167:00 amRNSDirector's share purchase
7th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20164:35 pmRNSResult of AGM
30th Sep 20167:00 amRNSResearch published in Clinical Chemistry
19th Sep 201611:14 amRNSIssue of Equity
9th Sep 20164:12 pmRNSAnnual Report and Accounts and Notice of AGM
4th Aug 20167:00 amRNSMD Anderson Cancer Center poster presentation
2nd Aug 20163:37 pmRNSEdison issues ADR update on Angle
28th Jul 20167:00 amRNSUse of Parsortix in GANNET53 drug trial
28th Jul 20167:00 amRNSPreliminary Results
27th Jul 20167:00 amRNSInitiation of 200 patient US ovarian cancer study
19th Jul 20167:00 amRNSInitiation of European ovarian cancer study
15th Jul 20167:00 amRNSNotice of Results
15th Jul 20167:00 amRNSParsortix gaining traction at EACR Conference
1st Jun 20163:04 pmRNSHolding(s) in Company
31st May 20164:36 pmRNSHolding(s) in Company
27th May 20163:12 pmRNSEdison issues research update on Angle
25th May 20167:00 amRNSCancer Research UK Contract
25th May 20167:00 amRNSPlacing
29th Apr 20167:00 amRNSNEW PUBLICATIONS UTILISING PARSORTIX
19th Apr 201612:43 pmRNSEdison issues research update on Angle
18th Apr 20167:00 amRNSParsortix potential in metastatic breast cancer
21st Mar 201612:12 pmRNSEdison issues research update on Angle
21st Mar 20167:00 amRNSParsortix potential for prostate cancer detection
9th Mar 20167:00 amRNSEuropean patent grant for Parsortix
28th Jan 20167:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.